PMID- 14625174
OWN - NLM
STAT- MEDLINE
DCOM- 20040331
LR  - 20151119
IS  - 1000-2588 (Print)
IS  - 1000-2588 (Linking)
VI  - 23
IP  - 11
DP  - 2003 Nov
TI  - [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
PG  - 1149-50
AB  - OBJECTIVE: To compare the therapeutic effects of STI 571 in treating Philadelphia 
      chromosome (Ph)-positive patients with chronic-phase and acceleration phase 
      chronic myeloid leukemia (CML-CP and CML-AP, respectively). METHODS: A total of 
      19 CML patients with Ph chromosome and/or fluorescence in situ hybridization 
      (FISH)-bcr/abl fusion gene positivity rates over 90% and a median age of 38 years 
      were recruited in this study, 12 of whom had previously failed to respond to 
      interferon-alpha. Five of the 19 patients were in accelerated phase and 14 in 
      chronic phase, 9 of the latter patient group in early stage of CML-CP (within 1 
      year since diagnosis) and 5 in advanced stage (3-6 years since diagnosis). All 
      the patients were given oral STI 571 at the dose of 300-500 mg/d for a median 
      treatment course of 5 months, and the 5 patients with CML-AP also received 
      homoharringtonine at dose of 1-2 mg/d for an average of 1.5 treatment cycles 
      (7-14 d for a complete treatment cycle). The Ph chromosome and the FISH-bcr/abl 
      were analysed again 3 months after the treatment. RESULTS: STI 571 induced 100% 
      complete hematological remission (CHR) and 79% major cytogenetic responses (MCR) 
      in these patients. The complete cytogenetic remission (CCR) rates of CML-AP 
      patients and CML-CP patients in advanced stage were lower than that of CML- CP 
      patients in early stage (0% and 40% vs 88.9%). CONCLUSION: STI 571 can achieve 
      high rate of CHR and MCR in CML-CP patients, especially in those in early stage 
      of the disease.
FAU - Meng, Fan-yi
AU  - Meng FY
AD  - Department of Hematology, Nanfang Hospital, First Military Medical University, 
      Guangzhou 510515, China. mengfu@medmail.com.cn
FAU - Zheng, Wei-yang
AU  - Zheng WY
FAU - Liu, Xiao-li
AU  - Liu XL
FAU - Xu, Bing
AU  - Xu B
FAU - Song, Lan-lin
AU  - Song LL
FAU - Zhang, Yu
AU  - Zhang Y
FAU - Huang, Fen
AU  - Huang F
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Di Yi Jun Yi Da Xue Xue Bao
JT  - Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
JID - 9426110
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Benzamides
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/*drug therapy/genetics
MH  - Leukemia, Myeloid, Chronic-Phase/blood/*drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Pyrimidines/adverse effects/*therapeutic use
EDAT- 2003/11/20 05:00
MHDA- 2004/04/01 05:00
CRDT- 2003/11/20 05:00
PHST- 2003/11/20 05:00 [pubmed]
PHST- 2004/04/01 05:00 [medline]
PHST- 2003/11/20 05:00 [entrez]
PST - ppublish
SO  - Di Yi Jun Yi Da Xue Xue Bao. 2003 Nov;23(11):1149-50.